Serum Pro- and Antiangiogenic Factors in Patients with Types I and II of Rosacea
Andrzej Jaworek1*, Maciej Patuszczak1, Jolanta Jaworek2, Adam Zalewski1 and Anna Wojas-Pelc1
1Department of Dermatology in Cracow, Uniwersytet Jagiellonski w Krakowie Collegium Medicum, Poland
2Faculty of Health Sciences, Uniwersytet Jagiellonski w Krakowie, Poland
Rosacea is a chronic inflammatory disease of the face’s skin, characterized by erythema papules, pustules and phymatous changes. There are four types of this disease (erythematoteleangiectatic-ETR, papulo-pustular- PPR, ocular rosacea and type with domination of phymatous changes). The treatment of rosacea involved use of systemic and topical antibiotics, isotretinoin, metronidazole, and suitable dermocosmetics and sunscreens. The pathogenesis of rosacea is still unknown. The undesired angiogenesis and misbalanced ratio between proangiogenic (VEGF) and antiangiogenic (endostatin) factors could be among the pathomechnisms of this ailment.
To assess the serum concentrations of some factors affecting angiogenesis in patients with rosacea.
72 patients with type ETR and PPR of rosacea (28 men, 44 women) and 21 healthy volunteers were involved in the study (28 men, 44 women). Blood samples were taken to measure the concentrations of VEGF, endostatin, IL-6 and TNF-α by ELISA.
Patients with rosacea have significantly higher serum level of VEGF than the control group (324.1 ± 33.0 vs. 21 238.6 ± 43,7pg/mL), whereas serum endostatin was reduced (261.2 ± 50.4 vs. 411.5 ± 40.2). Serum levels of IL-6 in rosacea patients was higher than in control group (2.82 ± 0.5 vs. 1.28 ± 0.25 pg/mL). No significant differences in the serum level of TNF-α in patients with rosacea have been noticed.
Increased production of proangiogenic factors; VEGF and IL-6 together with reduced antiangiogenic endostatin could be responsible, at least in part, for intensive angiogenesis and erythema in patients with rosacea. Further studies are needed to clarify the mechanism of this impaired angiogenesis to create the effective therapeutic strategy.
Rosacea; TNF alpha; VEGF; IL-6; Angiostatin
Read the whole article in the PDF file BELOW
© 2018 Jaworek A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.